TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05129384

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: B. infantis EVC001 or Lactose Placebo
Description: Infant probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B. infantis EVC001 or Lactose Placebo
Description: Infant probiotic
Study: NCT05639712

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient is given standardized questions about their well-being and affective state before and after the administration of placebo intravenously. This is carried out on the operating table right before anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 2.5 mg i.v.
Description: The patient is given standardized questions about their well-being and affective state before and after the administration of 2.5 mg morphine intravenously. This is carried out on the operating table right before anesthesia
Study: NCT00803088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Alair System
Description: Treatment of airways with the Alair System
Study: NCT05424692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate
Description: Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
Study: NCT04920448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Administered as specified in the treatment arm
Study: NCT04827537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20-hydroxyecdysone Oral
Description: 100 mg (one pill) x two times a day orally, 10 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Oral
Description: 500 mg (one pill) x two times a day orally, 10 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral
Description: 100 mg (one pill) x two times a day orally, 10 consecutive days
Study: NCT05639712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 5 mg i.v.
Description: The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 5 mg intravenously . This is carried out on the operating table right before anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 10 mg i.v.
Description: The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 10 mg intravenously . This is carried out on the operating table right before anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 2.5 mg i.v.
Description: The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 2.5 mg intravenously . This is carried out on the operating table right before anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 5 mg i.v.
Description: The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 5 mg intravenously . This is carried out on the operating table right before anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 10 mg i.v.
Description: The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 10 mg intravenously . This is carried out on the operating table right before anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl 0.025 mg i.v.
Description: The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.025 mg intravenously . This is carried out on the operating table right before anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl 0.05 mg i.v.
Description: The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.05 mg intravenously . This is carried out on the operating table right before anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl 0.1 mg i.v.
Description: The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.1 mg intravenously . This is carried out on the operating table right before anesthesia
Study: NCT06304727

Intervention type: OTHER
Intervention: clinical data review
Description: Medical records review to gather and analyze demographic, clinical, care and virological data
Study: NCT05163886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAM-002A
Description: LAM-002A (apilimod dimesylate) is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, size 0.
Study: NCT05888337

Intervention type: DEVICE
Intervention: Contoura LASIK with Phorcides planning strategy
Description: Bilateral treatment with topography guided LASIK
Study: NCT05163886

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose in Swedish orange, size 0 capsules.
Study: NCT05888337

Intervention type: DEVICE
Intervention: Contoura LASIK with manifest refraction planning strategy
Description: Bilateral treatment with topography guided LASIK
Study: NCT05250726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MENISC-T
Description: Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of meniscus used as interposition at the STT joint
Study: NCT04912531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Realty using a Microsoft Hololens, Empatica HR wristband, and EEG
Description: The investigators will use a DeepReality VR with biofeedback using a Microsoft Hololens, Empatica HR wristband and EEG. The Empatica HR wristband will measure HR and the EEG will measure alpha and theta brain waves. To monitor the physiologic data in real-time, data from the EEG and heart rate monitor will be streamed and processed in an Android Application that the investigators previously developed. During data collection, the Android app sends data via OSC to a specific IP and port, which is then collected in the game engine, Unity 3D and processed to adapt the virtual environment. Importantly, each device is inexpensive and can be sanitized and reused by multiple patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Essence Olfactory Necklace
Description: The Essence Olfactory Necklace holds a small, lightweight 7 ml capsule that contains an essential oil. Within the capsule is a piezo electric transducer which allows us to control the release of scent via Bluetooth using a smartphone app. Each Essence Necklace will be paired with a google phone that the investigators will use to control the frequency and intensity of scent for each patient. The investigators will limit the frequency to one burst of scent every 20 seconds to avoid habituation. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water). The investigators chose lavender because in our previous studies, \>97% of users enjoyed the lavender scent. The Essence Necklace is powered with a 3.7V Lithium Battery and has a battery lifetime of approximately 6 hours. The RC can easily recharge the Essence Necklace through a USB micro connector. Additionally, the Essence Necklace can be easily sanitized and reused by multiple patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bedside Olfaction Device
Description: The bedside olfaction device can be clipped on to the side of the patient's bed or beside table. The RC will turn on the night-time olfactory device at 7 pm and will turn off the device at 7 am. When turned on, the device releases scent once every 60 seconds. However, the frequency and intensity of the scent will be adjusted to the patient's preferences. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water).
Study: NCT05093166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ex vivo expanded autologous human oral epithelium containing stem cells
Description: The treatment includes a single administration of investigational product through a dedicated surgical procedure of penis wound bed preparation, epithelial surface adaption and product application followed by urethra tubularization and penis reconstruction.
Study: NCT05726279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS based personalized blood pressure management
Description: In lieu of predetermined blood pressure treatment thresholds, an optimal MAP range will be chosen based on limits of autoregulation calculated in real-time for the previous four hours for each participant. Choice of medications and dosing will be left to the primary clinical obstetrics team.
Study: NCT05128448

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross-body stretch (CBS)
Description: CBS is a self administered stretch that aims to stretch posterior shoulder structures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilisation with movement (MWM)
Description: WMW is a musculoskeletal procedure that aims to improve restricted and/or painful range of movement
Study: NCT05933876

Intervention type: DIAGNOSTIC_TEST
Intervention: To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR).
Description: Analyze clinical data, medical images and molecular circulating features to propose which variables serve to select the patients that will achieve complete response after SABR.

Intervention type: DIAGNOSTIC_TEST
Intervention: To propose a diagnostic test to determine the effectiveness of SABR.
Description: Collect blood samples at five different time points before and after treatment and analyze circulating tumoral DNA, medical images, and metabolites to monitor the effect of SABR and its effectiveness.

Intervention type: DIAGNOSTIC_TEST
Intervention: To propose a diagnostic test for Oligometastatic Cancer (OC).
Description: Analyze circulating tumoral DNA and metabolites from blood samples in search of the profile of OC.

Intervention type: DIAGNOSTIC_TEST
Intervention: To propose a diagnostic test for Oligometastatic Cancer (OC).
Description: Analyze circulating tumoral DNA and metabolites from blood samples in search of the profile of OC.
Study: NCT04981262

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stimulance
Description: Intervention with Prebiotic supplement
Study: NCT05180669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OARSCM Software Application
Description: Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
Study: NCT05226078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive behavioral treatment of insomnia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive behavioral treatment of insomnia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive behavioral treatment of insomnia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive behavioral treatment of insomnia
Study: NCT05966922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Stimulation
Description: Electrical Stimulation and a sham will be administered through the skin in random consecutive sessions in a study group. A single monophasic square electrical pulse and transcutaneous electrical nerve stimulation will be applied to the forearm volar aspect.
Study: NCT03625973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3D-RT
Description: Objects printed using 3D printing media will be used as stimuli in Reminiscence Therapy
Study: NCT06389591

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)
Description: pp65 RNA loaded lipid particles or pp65 RNA-LPs administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)
Description: pp65 RNA loaded lipid particles or pp65 RNA-LPs administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)
Description: personalized tumor mRNA, pp65 fl LAMP mRNA and DOTAP liposomes or RNA loaded lipid particles, RNA-LPs administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)
Description: personalized tumor mRNA, pp65 fl LAMP mRNA and DOTAP liposomes or RNA loaded lipid particles, RNA-LPs administered intravenously
Study: NCT05268120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline 200 mg q.d. - rifampicin 600mg b.i.d.
Description: Both first choice treatments in Dutch guideline for MRSA decolonization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d.
Description: Both first choice treatments in Dutch guideline for MRSA decolonization
Study: NCT04679376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 40 mg daily administered orally in tablet or capsule form
Study: NCT06465602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: The subjects will receive 1.5 grams per day of Nicotinamide, orally, for 30 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will receive 1.5 grams per day of placebo, orally, for 30 days.
Study: NCT03625973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3D-RT
Description: Objects printed using 3D printing media will be used as stimuli in Reminiscence Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RT-Verbal
Description: Verbal cues will be used as stimuli in Reminiscence Therapy
Study: NCT05280288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone@BC app
Description: Participants in the intervention group will be asked to use the Bone@BC app daily it will take them 1-3 minutes to answer the daily questions in the app concerning symptoms and physical activity. They will have access to a Questionnaire Prompt List in the app Bone@BC.
Study: NCT05569889

Intervention type: PROCEDURE
Intervention: Anterior Cruciate Ligament reconstruction (ACLR)
Description: A comparison between the two groups were done regarding the three following stages: (a) the preparation time of the trolley, which is the time taken by the CNOR to recover from the reserves all the single-packed sterile instruments (SPSI) necessary for the intervention or to recover the CST (b) the opening time of the instruments by the circulating nurse who opens the packages and gives them to the surgical nurse while respecting the sterility of the items, and by the surgical nurse who prepares the table for the intervention, and (c) the sorting time of the waste between plastic and paper at the end of the intervention.

Intervention type: PROCEDURE
Intervention: Anterior Cruciate Ligament reconstruction (ACLR)
Description: A comparison between the two groups were done regarding the three following stages: (a) the preparation time of the trolley, which is the time taken by the CNOR to recover from the reserves all the single-packed sterile instruments (SPSI) necessary for the intervention or to recover the CST (b) the opening time of the instruments by the circulating nurse who opens the packages and gives them to the surgical nurse while respecting the sterility of the items, and by the surgical nurse who prepares the table for the intervention, and (c) the sorting time of the waste between plastic and paper at the end of the intervention.
Study: NCT06567301

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy combined with Chitosan nanoparticles gel
Description: Gymna - Belgian
Study: NCT05180669

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: MyMAT Software Application
Description: Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
Study: NCT05285852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling technique is maneuvered by different skilled health practitioners aiming to reduce central sensitization, i.e., the hypersensitivity to pain of the central nervous system. It is also apprehended to reduce the local and referred pain, and improve the muscle activation patterns leading to improved range of motion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dry Needling
Description: Placebo Dry Needling only causes a pricking sensation
Study: NCT05431686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMA visits
Description: SMA visit once every 3 months over a 12 month period
Study: NCT06567301

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound therapy combined with Chitosan nanoparticles gel
Description: Gymna - Belgian

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound therapy combined with Chitosan nanoparticles gel
Description: Gymna - Belgian
Study: NCT05870475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib at a starting dose of 10mg, orally administered twice daily. If ruxolitinib is not tolerated, cross-over to the pegylated interferon α-2b alone group is allowed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon α-2b
Description: Starting dose of 180ug, subcutaneous injection once a week. If complete hematological remission is not achieved after 12 weeks of treatment with pegylated interferon α-2b alone, cross-over to the pegylated interferon α-2b plus ruxolitinib group is allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon α-2b
Description: Starting dose of 180ug, subcutaneous injection once a week. If complete hematological remission is not achieved after 12 weeks of treatment with pegylated interferon α-2b alone, cross-over to the pegylated interferon α-2b plus ruxolitinib group is allowed.
Study: NCT05761327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: In the Mediterranean diet; The frequency of consumption of foods such as olive oil, olives, nuts, fish, vegetables and fruits will be given in accordance with the Mediterranean diet pyramid. During the study, it is planned to develop new recipes suitable for the nutritional habits of the individual. The researcher will be able to reach the researcher 7/24 in case of any problem experienced by the individual, and the participant's questions will be answered. Nutrition counseling to this group will be supported by an oral explanation given by the dietitian.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: In the Mediterranean diet; The frequency of consumption of foods such as olive oil, olives, nuts, fish, vegetables and fruits will be given in accordance with the Mediterranean diet pyramid. During the study, it is planned to develop new recipes suitable for the nutritional habits of the individual. The researcher will be able to reach the researcher 7/24 in case of any problem experienced by the individual, and the participant's questions will be answered. Nutrition counseling to this group will be supported by an oral explanation given by the dietitian.
Study: NCT06382662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metaxalone m640
Description: A single dose of micronize metaxalone 640 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tizanidine
Description: A single dose of tizanidine 8 mg
Study: NCT05655507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zuranolone
Description: Administered as capsules
Study: NCT05741710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylone
Description: Methylone capsules, given orally, once a week for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules to match methylone, given orally, once a week for 4 weeks. NOTE: Placebo is only in Part B
Study: NCT06121635

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Direct Current Stimulation and Transcranial Direct Current Stimulation
Description: At the robot-assisted gait training, 20-minute gait training for the patient at an appropriate speed with the Locohelp Woodway device. The aim is to re-teach proper walking, gait cycle timing, and create a near-normal gait pattern through multiple repetitions. Robot-assisted gait training will be performed immediately following the stimulation applied to the patients.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Direct Current Stimulation and Transcranial Direct Current Stimulation
Description: At the robot-assisted gait training, 20-minute gait training for the patient at an appropriate speed with the Locohelp Woodway device. The aim is to re-teach proper walking, gait cycle timing, and create a near-normal gait pattern through multiple repetitions. Robot-assisted gait training will be performed immediately following the stimulation applied to the patients.

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Sham ts-DCS and sham t-DCS
Description: Sham ts-DCS and sham t-DCS
Study: NCT05530915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gel capsule
Description: Single capsule per dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gel capsule
Description: Single capsule per dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gel capsule
Description: Single capsule per dose
Study: NCT04887805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Mesylate
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT06297343

Intervention type: PROCEDURE
Intervention: Creation of an arteriovenous fistula
Description: Patients will undergo the surgical procedure to create an arteriovenous fistula and will be discharged the same day (outpatient care, or an overnight stay in hospital if they live a long way from the hospital, have multiple pathologies or are socially isolated). An arteriovenous fistula is created under local or general anaesthetic. On the day of the operation, the type of arteriovenous fistula created, the side of the arteriovenous fistula, the location of the arteriovenous fistula and the patency of the arteriovenous fistula will be collected.